Improving the Management of HIV Disease Vol. 6, no. 5 [World Conference on AIDS (12th: 1998: Geneva)]

International AIDS Society-USA

Paul A. Volberding, MD
Professor of Medicine
University of California San Francisco
San Francisco, California
Constance A. Benson, MD
Professor of Medicine
University of Colorado School of Medicine
Denver, Colorado
Peter C. Cassat, JD
Associate
Dow, Lohnes, & Albertson
Washington, DC

Margaret A. Fischl, MD
Professor of Medicine
University of Miami School of Medicine
Miami, Florida
Harold A. Kessler, MD
Professor of Medicine and Immunology/
Microbiology
Rush Medical College
Chicago, Illinois
Douglas D. Richman, MD
Professor of Pathology and Medicine
University of California San Diego and
San Diego Veterans Affairs Medical Center
San Diego, California

Michael S. Saag, MD
Professor of Medicine
University of Alabama at Birmingham
Birmingham, Alabama
Robert T. Schooley, MD
Professor of Medicine
University of Colorado School of Medicine
Denver, Colorado

Donna M. Jacobsen
Executive Director
International AIDS Society-USA
San Francisco, California

ABOUT THIS ISSUE...
This issue of Improving the Management of HIV Disease spotlights the
recent IAS-USA symposium at the 12th
Conference on AIDS in Geneva, which
presented a unique opportunity for the
IAS-USA panels on antiretroviral therapy and HIV resistance testing to present their latest recommendations and
discuss their implications for clinical
practice (see Hirsch et al. ]AMA.
1998;279:1984. Carpenter et al. JAMA.
1998;280:78-86; reprints of these papers were provided in the July issue of
this publication). The symposium was
largely dedicated to addressing clinical
issues within the context of specific
case examples that illustrated how the
panel's various recommendations are
applied. This issue includes a summary
of these discussions in an effort to supplement the recommendations with direct, case-based experiences.
The Resistance Testing Panel was
convened last year to assess the impact
of these new technologies in HIV management. The Antiretroviral Therapy
Panel revised their recommendations to
account for new data indicating that
eradication with current regimens was

not possible, that there will be longterm side effects with these therapies,
and that regimens need to be tailored to
individual patient needs.
Questions were also collected from
the audience, and are addressed by the
panel members in this issue. These responses are part of an ongoing effort to
keep the recommendations of both panels up-to-date and clinically relevant,
and are also meant to complement the
respective guidelines by addressing
some of the more ambiguous and complex aspects of HIV care.
The development of the antiretroviral therapy and
resistance testing guidelines was supported directly by the International AIDS Society-USA.
The symposium in Geneva and this issue of Improving the Management of HIV Disease are
made possible by unrestricted educational grants
from the following:
Major grants from
Agouron Pharmaceuticals
Bristol-Myers Squibb
Glaxo Wellcome
Substantial grants from
Roche Laboratories
Roxane Labs/Boehringer Ingelheim
Generous grant from
DuPont Pharmaceuticals

Improving the Management
of HIV Disease is published
by the International AIDS Society-USA (IAS-USA). The
views and opinions expressed in this publication
are those of the contributors
and do not necessarily reflect
the views or recommendations of the IAS-USA. Unrestricted educational grant
support for this publication
was received from several
commercial companies. All
symposia faculty and publication contributors have provided disclosures of financial
interests, and this information
is available from IAS-USA by
request.
This publication may contain information about the investigational uses of drugs or
products that are not approved by the US Food and
Drug Administration. Please
consult full prescribing information before using any
medication or product mentioned in this publication.